Compare · QCLS vs QDEL
QCLS vs QDEL
Side-by-side comparison of Q/C Technologies Inc. (QCLS) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QCLS and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- QDEL carries a market cap of $4.24B.
- QDEL has been more active in the news (9 items in the past 4 weeks vs 7 for QCLS).
- QDEL has more recent analyst coverage (18 ratings vs 0 for QCLS).
- Company
- Q/C Technologies Inc.
- QuidelOrtho Corporation
- Price
- -
- -
- Market cap
- -
- $4.24B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 7
- 9
- Recent ratings
- 0
- 18
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest QCLS
- SEC Form 4 filed by White Billy Joe
- SEC Form 4 filed by Friscia Stephen
- SEC Form 4 filed by Voss Chelsea Sierra
- SEC Form 4 filed by Bernstein Bruce
- SEC Form 4 filed by Glass Mitchell
- SEC Form 4 filed by Silverman Joshua
- SEC Form 10-K filed by Q/C Technologies Inc.
- SEC Form NT 10-K filed by Q/C Technologies Inc.
- Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference
- Q/C Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Latest QDEL
- Chief Operations Officer Mclellan Philip D. was granted 3,238 shares and covered exercise/tax liability with 1,162 shares, increasing direct ownership by 11% to 21,250 units (SEC Form 4) (for tax liability)
- EVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 3,508 shares and covered exercise/tax liability with 1,269 shares, increasing direct ownership by 249% to 3,139 units (SEC Form 4) to cover taxes
- Understanding and Addressing Syphilis Trends - and What's Being Missed
- SEC Form 4 filed by Sisitsky Nathaniel
- TTP Group Announces the Sale of LEX Diagnostics
- QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- SEC Form 3 filed by new insider Sisitsky Nathaniel